Cajal Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 10

Cajal Therapeutics General Information

Description

Developer of disease-altering therapies designed for the treatment of neurodegenerative and iron-related disorders. The company integrates human genetics, multi-omics, next-generation sequencing, and imaging technologies to identify drug targets, providing patients with small-molecule and RNA medicines intended to restore iron homeostasis and metabolic function.

Contact Information

Website
www.cajal-tx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 300/300A
  • Seattle, WA 98109
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 300/300A
  • Seattle, WA 98109
  • United States

Cajal Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cajal Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 29-May-2026 Completed Clinical Trials - General
2. Later Stage VC (Series B) 04-Feb-2025 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 29-Nov-2022 $95.7M $95.7M Completed Pre-Clinical Trials
To view Cajal Therapeutics’s complete valuation and funding history, request access »

Cajal Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Cajal Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Cajal Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of disease-altering therapies designed for the treatment of neurodegenerative and iron-related disorders. The
Drug Discovery
Seattle, WA
31 As of 2026

Seattle, WA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cajal Therapeutics Competitors (56)

One of Cajal Therapeutics’s 56 competitors is AltPep, a Venture Capital-Backed company based in Seattle, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AltPep Venture Capital-Backed Seattle, WA
CereSpir Venture Capital-Backed New York, NY
Alzheon Venture Capital-Backed Framingham, MA
TauRx Pharmaceuticals Private Equity-Backed Aberdeen, United Kingdom
Casma Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 56 competitors. Get the full list »

Cajal Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cajal Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
Bristol-Myers Squibb Corporation Minority
Deviation Capital Venture Capital Minority
Dolby Family Ventures Venture Capital Minority
Evotec Corporation Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Cajal Therapeutics FAQs

  • When was Cajal Therapeutics founded?

    Cajal Therapeutics was founded in 2020.

  • Where is Cajal Therapeutics headquartered?

    Cajal Therapeutics is headquartered in Seattle, WA.

  • What is the size of Cajal Therapeutics?

    Cajal Therapeutics has 31 total employees.

  • What industry is Cajal Therapeutics in?

    Cajal Therapeutics’s primary industry is Drug Discovery.

  • Is Cajal Therapeutics a private or public company?

    Cajal Therapeutics is a Private company.

  • What is Cajal Therapeutics’s current revenue?

    The current revenue for Cajal Therapeutics is .

  • How much funding has Cajal Therapeutics raised over time?

    Cajal Therapeutics has raised $136M.

  • Who are Cajal Therapeutics’s investors?

    Alexandria Venture Investments, Bristol-Myers Squibb, Deviation Capital, Dolby Family Ventures, and Evotec are 5 of 10 investors who have invested in Cajal Therapeutics.

  • Who are Cajal Therapeutics’s competitors?

    AltPep, CereSpir, Alzheon, TauRx Pharmaceuticals, and Casma Therapeutics are some of the 56 competitors of Cajal Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process